Define Optimized Analytical Approaches to Verify Oligonucleotide Impurities
& Meet Regulatory Expectations from Raw Materials to Scale Up

Uniting Biotech & Pharma Experts to Exchange Insights on Oligonucleotide Analytical
Development & CMC

Despite milestone progress, such as Avidity securing breakthrough designation for their oligo conjugate, significant challenges persist across the oligo landscape in impurity profiling, drug characterisation, efficient scale-up, and regulatory alignment.

Join 80+ industry experts from analytical development, process development, CMC, analytical chemistry, and quality control at the 4th Oligonucleotide Analytical Development & CMC Summit to collaborate, networ,k and learn cutting-edge strategies that are tackling the unique challenges in oligo analytical development and CMC scale-up.

Gain actionable insight from case studies, presentations and deep dive discussions from Sarepta, Ionis, Biogen, Novo Nordisk, GSK, Wave Life Science, Denali, PepGen, Avidity, Alnylam and more, to advance and reshape the future of oligonucleotide drug development.

EVENT GUIDE
REGISTER
PARTNER

World-Class Speaker Faculty Includes:

Bao Cai

Executive Director of Process Development

Sarepta Therapeutics

Evan Santos

Senior Research Associate, Manufacturing & Operations

Ionis Pharmaceuticals, Inc.

George Bou-Assaf

Associate Director Analytical & CMC Development

Biogen

Lianxiu Guan

Senior Principal Scientist

Amgen Inc.

Matt McQueen

scientist

Avidity Biosciences, Inc.

Philip Ross

Senior Director - Analytical Development , Quality Control & Chemistry, Manufacturing & Controls

Wave Life Sciences Ltd.

SPEAKER FACULTY 2025

Previously Attending Companies Include:

“Very intimate conference. Felt connected to the speakers and they were all very approachable and provided excellent dialog.”- Analytical Development Manager at Novo Nordisk

Other Events in the Series:

EVENT GUIDE
REGISTER
PARTNER